Sep 2026
OX40 ligand-engineered dendritic cell nanovesicles potentiate antitumor immunity through dual-mode T cell activation.
The efficacy of classical dendritic cell (DC)-based cancer vaccines is limited by poor in vivo stability, inefficient lymph node delivery, and the immunosuppressive tumor microenvironment. Here, we developed a nanovaccine platform by engineering DC-derived nanovesicles (NVs) and established a membrane-anchoring strateg...
Zhong-Qian Yang, Yi-Ting Ding, Ying Yang et al.
· Journal of Controlled Releas... · 0 citations